RT Journal Article
SR Electronic
T1 Genomic reconstruction of the SARS-CoV-2 epidemic in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.22.21257633
DO 10.1101/2021.05.22.21257633
A1 Vöhringer, Harald S.
A1 Sanderson, Theo
A1 Sinnott, Matthew
A1 Maio, Nicola De
A1 Nguyen, Thuy
A1 Goater, Richard
A1 Schwach, Frank
A1 Harrison, Ian
A1 Hellewell, Joel
A1 Ariani, Cristina
A1 Gonçalves, Sonia
A1 Jackson, David
A1 Johnston, Ian
A1 Jung, Alexander W.
A1 Saint, Callum
A1 Sillitoe, John
A1 Suciu, Maria
A1 Goldman, Nick
A1 Panovska-Griffiths, Jasmina
A1 The Wellcome Sanger Institute Covid-19 Surveillance Team
A1 The COVID-19 Genomics UK (COG-UK) Consortium
A1 Birney, Ewan
A1 Volz, Erik
A1 Funk, Sebastian
A1 Kwiatkowski, Dominic
A1 Chand, Meera
A1 Martincorena, Inigo
A1 Barrett, Jeffrey C.
A1 Gerstung, Moritz
YR 2021
UL http://medrxiv.org/content/early/2021/08/17/2021.05.22.21257633.abstract
AB The evolution of the SARS-CoV-2 pandemic continuously produces new variants, which warrant timely epidemiological characterisation. Here we use the dense genomic surveillance generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of sub-epidemics that peaked in the early autumn of 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. Alpha grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed Alpha and eliminated nearly all other lineages in early 2021. However, a series of variants (mostly containing the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. Accounting for sustained introductions, however, indicates that their transmissibility is unlikely to have exceeded that of Alpha. Finally, B.1.617.2/Delta was repeatedly introduced to England and grew rapidly in the early summer of 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on June 26.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. We would like to thank our colleagues at EMBL-EBI, the Wellcome Sanger Institute and from COG-UK for stimulating discussions and helpful comments on this manuscript. HSV and MG are supported by a grant from the Department of Health and Social Care. AWJ, EB and MG are beneficiaries from grant NNF17OC0027594 from the Novo Nordisk Foundation. TS is supported by grant 210918/Z/18/Z, and JH and SF by grant 210758/Z/18/Z from the Wellcome Trust. HSV, NDM, AWJ, NG, EB and MG are supported by EMBL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was done as part of surveillance for COVID-19 under the auspices of Section 251 of the National Health Service Act 2006. It therefore did not require individual patient consent or ethical approval. The COVID-19 Genomics UK (COG-UK) study protocol was approved by the Public Health England Research Ethics Governance Group.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPCR test data are publicly available at https://coronavirus.data.gov.uk/. SARS-CoV-2 genome data and geolocations can be obtained under controlled access from https://www.cogconsortium.uk/data/. A filtered, privacy conserving version of the data set is publicly available at https://covid19.sanger.ac.uk/downloads. The data and a version of the analysis with fewer lineages can be interactively explored at https://covid19.sanger.ac.uk. https://coronavirus.data.gov.uk/ https://www.cogconsortium.uk/data/ https://covid19.sanger.ac.uk/downloads https://covid19.sanger.ac.uk